We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Gilead Sciences (GILD) Ascends But Remains Behind Market: Some Facts to Note
Read MoreHide Full Article
In the latest trading session, Gilead Sciences (GILD - Free Report) closed at $75.06, marking a +0.43% move from the previous day. The stock trailed the S&P 500, which registered a daily gain of 0.63%. On the other hand, the Dow registered a gain of 0.59%, and the technology-centric Nasdaq increased by 0.39%.
Coming into today, shares of the HIV and hepatitis C drugmaker had lost 1.66% in the past month. In that same time, the Medical sector lost 1.62%, while the S&P 500 lost 3.39%.
Investors will be eagerly watching for the performance of Gilead Sciences in its upcoming earnings disclosure. The company is forecasted to report an EPS of $1.92, showcasing a 1.05% upward movement from the corresponding quarter of the prior year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $6.76 billion, down 3.94% from the year-ago period.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $6.64 per share and revenue of $26.78 billion, indicating changes of -8.54% and -1.82%, respectively, compared to the previous year.
Investors should also take note of any recent adjustments to analyst estimates for Gilead Sciences. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 0.07% upward. Gilead Sciences currently has a Zacks Rank of #3 (Hold).
In the context of valuation, Gilead Sciences is at present trading with a Forward P/E ratio of 11.26. This denotes a discount relative to the industry's average Forward P/E of 17.38.
One should further note that GILD currently holds a PEG ratio of 0.8. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. As the market closed yesterday, the Medical - Biomedical and Genetics industry was having an average PEG ratio of 2.13.
The Medical - Biomedical and Genetics industry is part of the Medical sector. With its current Zacks Industry Rank of 83, this industry ranks in the top 33% of all industries, numbering over 250.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Gilead Sciences (GILD) Ascends But Remains Behind Market: Some Facts to Note
In the latest trading session, Gilead Sciences (GILD - Free Report) closed at $75.06, marking a +0.43% move from the previous day. The stock trailed the S&P 500, which registered a daily gain of 0.63%. On the other hand, the Dow registered a gain of 0.59%, and the technology-centric Nasdaq increased by 0.39%.
Coming into today, shares of the HIV and hepatitis C drugmaker had lost 1.66% in the past month. In that same time, the Medical sector lost 1.62%, while the S&P 500 lost 3.39%.
Investors will be eagerly watching for the performance of Gilead Sciences in its upcoming earnings disclosure. The company is forecasted to report an EPS of $1.92, showcasing a 1.05% upward movement from the corresponding quarter of the prior year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $6.76 billion, down 3.94% from the year-ago period.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $6.64 per share and revenue of $26.78 billion, indicating changes of -8.54% and -1.82%, respectively, compared to the previous year.
Investors should also take note of any recent adjustments to analyst estimates for Gilead Sciences. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 0.07% upward. Gilead Sciences currently has a Zacks Rank of #3 (Hold).
In the context of valuation, Gilead Sciences is at present trading with a Forward P/E ratio of 11.26. This denotes a discount relative to the industry's average Forward P/E of 17.38.
One should further note that GILD currently holds a PEG ratio of 0.8. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. As the market closed yesterday, the Medical - Biomedical and Genetics industry was having an average PEG ratio of 2.13.
The Medical - Biomedical and Genetics industry is part of the Medical sector. With its current Zacks Industry Rank of 83, this industry ranks in the top 33% of all industries, numbering over 250.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.